
CTI BioPharma Corp. CTIC
Quarterly report 2023-Q1
added 05-16-2026
CTI BioPharma Corp. Interest Expense 2011-2026 | CTIC
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense CTI BioPharma Corp.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.1 M | 2.42 M | 828 K | 1 M | 1.21 M | 1.87 M | 2.61 M | 2.1 M | 1.95 M | 1.03 M | 56 K | 870 K | 2.21 M | 4.81 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.1 M | 56 K | 2.58 M |
Quarterly Interest Expense CTI BioPharma Corp.
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.18 M | - | 3.56 M | 3.76 M | 2.06 M | - | 531 K | 45 K | 68 K | - | 115 K | 137 K | 167 K | - | 240 K | 269 K | 294 K | - | 308 K | 297 K | 288 K | - | 457 K | 488 K | 534 K | - | 634 K | 677 K | 714 K | - | 1.29 M | 597 K | 494 K | - | 472 K | 467 K | 464 K | - | 316 K | 316 K | 48 K | - | 43 K | 3 K | 55 K | - | 204 K | 262 K | 389 K | 385 K | 776 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.18 M | 3 K | 677 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
9.34 K | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
262 K | - | 1.35 % | $ 17.8 M | ||
|
Coherus BioSciences
CHRS
|
9 M | $ 1.45 | -7.94 % | $ 170 M | ||
|
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
16.4 M | - | - | $ 2.18 B | ||
|
Compugen Ltd.
CGEN
|
281 K | $ 2.1 | -5.41 % | $ 196 M | ||
|
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B | ||
|
BioNTech SE
BNTX
|
14.2 M | $ 88.08 | -1.69 % | $ 21.3 B | ||
|
Athira Pharma
ATHA
|
1.24 M | - | - | $ 269 M | ||
|
Galera Therapeutics
GRTX
|
11.4 M | - | -32.59 % | $ 7.61 M | ||
|
CRISPR Therapeutics AG
CRSP
|
86.6 M | $ 51.84 | -8.97 % | $ 4.66 B | ||
|
Berkeley Lights
BLI
|
910 K | - | -7.31 % | $ 87 M | ||
|
Celldex Therapeutics
CLDX
|
927 K | $ 28.62 | -4.38 % | $ 1.9 B | ||
|
IMV
IMV
|
2.34 K | - | - | $ 13.1 M | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
354 K | - | -4.36 % | $ 27 M | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
2.15 M | - | - | $ 384 M | ||
|
Gracell Biotechnologies
GRCL
|
6.74 M | - | - | $ 3.37 B | ||
|
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
561 K | $ 3.09 | -2.22 % | $ 5.09 M | ||
|
Aptinyx
APTX
|
737 K | - | -39.0 % | $ 4.57 M | ||
|
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
1.44 M | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
-43 K | - | - | $ 28.6 M | ||
|
Arcutis Biotherapeutics
ARQT
|
443 K | $ 21.23 | -3.28 % | $ 2.7 B | ||
|
Allena Pharmaceuticals
ALNA
|
-38 K | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-5.01 K | - | -11.43 % | $ 502 K |